Pharmaceutical News

RSS

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.

31 Aug 2010

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

Achaogen, a biopharmaceutical company discovering and developing innovative antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the award of a contract with The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

31 Aug 2010

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

Greater Sacramento Specialty Pharmacy acquired by The Apothecary Shops

The Apothecary Shops, a Phoenix-based chain of specialty pharmacies with 16 locations in six states, has acquired the Greater Sacramento Specialty Pharmacy (GSP), a customer-service focused pharmacy with primary specialties in oncology and pain management.

30 Aug 2010

H. D. Smith becomes primary supplier of pharmaceutical products for NAPPSA pharmacies

NAPPSA, a pharmacy buying group advancing the growing buying power of the Nigerian-owned independent retailers, today announced a new three-year prime vendor agreement with H. D. Smith, a leading national pharmaceutical wholesaler.

30 Aug 2010

Cannabis Science seeks entry into European medical cannabis market

Cannabis Science Inc., a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges.

30 Aug 2010

Perfadex improves survival in lung tranplant patients: Study

A recently published study in The Journal of Heart and Lung Transplantation shows that the patients who are most seriously ill before lung tranplantation have better one-year survival when Perfadex is used as the preservation solution for donor lungs compared with UW solution. Furthermore, the patients who received lungs preserved in Perfadex ran a significantly lower risk of being affected by rejection reactions requiring treatment.

30 Aug 2010

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.

30 Aug 2010

Eisai receives new action date for FDA priority review of eribulin mesylate NDA for metastatic breast cancer

Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.

30 Aug 2010

FDA approves additional strengths of SOLODYN for inflammatory lesions treatment

Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

30 Aug 2010

Children, teens need good health before the start of new school year, says medical director

With the back to school shopping season in full swing, it is also important to arm area children and teens with other tools they need to have a good school year- like medical exams. These are critical to good health and should take place before or shortly after the start of the new school year, and include a routine doctor's exam to confirm that all immunizations are up-to-date, a dental check-up, and a vision exam.

30 Aug 2010

CAMH welcomes Ontario's narcotics strategy to address inappropriate use of prescription opioids

The Government of Ontario's narcotics strategy will address the root causes of a significant and growing health problem - the inappropriate use of prescription opioids. The Centre for Addiction and Mental Health (CAMH) welcomes the strategy announced by The Honourable Deb Matthews, Minister of Health and Long-Term Care.

30 Aug 2010

Independent drugstore lobby demands more 'transparency' for PBMs in pharmacy supply chain

"Despite recent press revelations of its 'top secret' lobbying campaign to maintain the confidentiality of its own Medicaid pricing information, the independent drugstore lobby continues to demand more 'transparency' for others in the pharmacy supply chain, most notably PBMs.

30 Aug 2010

New research contradicts previous reports on blood-thinner clopidogrel

New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

30 Aug 2010

Promising skin cancer drug in the near horizon

A new drug has been developed to combat a deadly form of skin cancer – melanoma. The drug, PLX4032, was tested on 32 melanoma patients who had a key mutation in their tumors. 26 of these patients responded favorably says the study published in the New England Journal of Medicine.

30 Aug 2010

Misuse of OTC medicines increases risk for children

Many children are being put at risk by parents over-use of widely available over the counter (OTC) medicines for fever, coughs and colds, says a study from Australia to be presented to the annual conference of the International Pharmaceutical Federation (FIP) today (Monday 30 August).

30 Aug 2010

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel.

30 Aug 2010

Study finds common risk factors linked with painkiller addiction

A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.

30 Aug 2010

Pharmaceutical News

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

FDA extends Prescription Drug User Fee Act date for ezogabine

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

Greater Sacramento Specialty Pharmacy acquired by The Apothecary Shops

H. D. Smith becomes primary supplier of pharmaceutical products for NAPPSA pharmacies

Cannabis Science seeks entry into European medical cannabis market

Perfadex improves survival in lung tranplant patients: Study

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Eisai receives new action date for FDA priority review of eribulin mesylate NDA for metastatic breast cancer

FDA approves additional strengths of SOLODYN for inflammatory lesions treatment

Children, teens need good health before the start of new school year, says medical director

CAMH welcomes Ontario's narcotics strategy to address inappropriate use of prescription opioids

Independent drugstore lobby demands more 'transparency' for PBMs in pharmacy supply chain

New research contradicts previous reports on blood-thinner clopidogrel

Promising skin cancer drug in the near horizon

Misuse of OTC medicines increases risk for children

Study reveals impact of genetic make-up on response to oral antiplatelet treatment ticagrelor

Study finds common risk factors linked with painkiller addiction

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News